img

Global HIV Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global HIV Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

HIV is a type of retrovirus that causes serious complications in humans. It generally spreads via the blood, semen, vaginal fluid, pre-ejaculate, or breast milk. The global market for HIV drugs is envisaged to surpass USD 19,000 million by 2019 owing to the recent rise in HIV patient population.
The global HIV Drugs market size was US$ 23380 million in 2024 and is forecast to a readjusted size of US$ 26950 million by 2034 with a CAGR of 2.0% during the forecast period 2024-2034.
One of the primary factors catalyzing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.
In terms of sales (consumption) side, this report focuses on the sales of HIV Drugs by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global HIV Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global HIV Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
By Type
Multi-Class Combination Products
Nucleoside Reverse Transcriptase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Entry Inhibitors - CCR5 Co-Receptor Antagonist
HIV Integrase Strand Transfer Inhibitors
By Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of HIV Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of HIV Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, HIV Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 HIV Drugs Definition
1.2 Market by Type
1.2.1 Global HIV Drugs Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Multi-Class Combination Products
1.2.3 Nucleoside Reverse Transcriptase Inhibitors
1.2.4 Non-Nucleoside Reverse Transcriptase Inhibitors
1.2.5 Protease Inhibitors
1.2.6 Fusion Inhibitors
1.2.7 Entry Inhibitors - CCR5 Co-Receptor Antagonist
1.2.8 HIV Integrase Strand Transfer Inhibitors
1.3 Market Segment by Application
1.3.1 Global HIV Drugs Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global HIV Drugs Sales
2.1 Global HIV Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global HIV Drugs Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global HIV Drugs Revenue by Region
2.3.1 Global HIV Drugs Revenue by Region (2018-2023)
2.3.2 Global HIV Drugs Revenue by Region (2024-2034)
2.4 Global HIV Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global HIV Drugs Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global HIV Drugs Sales Quantity by Region
2.6.1 Global HIV Drugs Sales Quantity by Region (2018-2023)
2.6.2 Global HIV Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global HIV Drugs Sales Quantity by Manufacturers
3.1.1 Global HIV Drugs Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global HIV Drugs Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by HIV Drugs Sales in 2024
3.2 Global HIV Drugs Revenue by Manufacturers
3.2.1 Global HIV Drugs Revenue by Manufacturers (2018-2023)
3.2.2 Global HIV Drugs Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by HIV Drugs Revenue in 2024
3.3 Global HIV Drugs Sales Price by Manufacturers
3.4 Global Key Players of HIV Drugs, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global HIV Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of HIV Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of HIV Drugs, Product Offered and Application
3.8 Global Key Manufacturers of HIV Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global HIV Drugs Sales Quantity by Type
4.1.1 Global HIV Drugs Historical Sales Quantity by Type (2018-2023)
4.1.2 Global HIV Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global HIV Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global HIV Drugs Revenue by Type
4.2.1 Global HIV Drugs Historical Revenue by Type (2018-2023)
4.2.2 Global HIV Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global HIV Drugs Revenue Market Share by Type (2018-2034)
4.3 Global HIV Drugs Price by Type
4.3.1 Global HIV Drugs Price by Type (2018-2023)
4.3.2 Global HIV Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global HIV Drugs Sales Quantity by Application
5.1.1 Global HIV Drugs Historical Sales Quantity by Application (2018-2023)
5.1.2 Global HIV Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global HIV Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global HIV Drugs Revenue by Application
5.2.1 Global HIV Drugs Historical Revenue by Application (2018-2023)
5.2.2 Global HIV Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global HIV Drugs Revenue Market Share by Application (2018-2034)
5.3 Global HIV Drugs Price by Application
5.3.1 Global HIV Drugs Price by Application (2018-2023)
5.3.2 Global HIV Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America HIV Drugs Sales by Company
6.1.1 North America HIV Drugs Revenue by Company (2018-2023)
6.1.2 North America HIV Drugs Sales Quantity by Company (2018-2023)
6.2 North America HIV Drugs Market Size by Type
6.2.1 North America HIV Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America HIV Drugs Revenue by Type (2018-2034)
6.3 North America HIV Drugs Market Size by Application
6.3.1 North America HIV Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America HIV Drugs Revenue by Application (2018-2034)
6.4 North America HIV Drugs Market Size by Country
6.4.1 North America HIV Drugs Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America HIV Drugs Revenue by Country (2018-2034)
6.4.3 North America HIV Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe HIV Drugs Sales by Company
7.1.1 Europe HIV Drugs Sales Quantity by Company (2018-2023)
7.1.2 Europe HIV Drugs Revenue by Company (2018-2023)
7.2 Europe HIV Drugs Market Size by Type
7.2.1 Europe HIV Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe HIV Drugs Revenue by Type (2018-2034)
7.3 Europe HIV Drugs Market Size by Application
7.3.1 Europe HIV Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe HIV Drugs Revenue by Application (2018-2034)
7.4 Europe HIV Drugs Market Size by Country
7.4.1 Europe HIV Drugs Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe HIV Drugs Revenue by Country (2018-2034)
7.4.3 Europe HIV Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China HIV Drugs Sales by Company
8.1.1 China HIV Drugs Sales Quantity by Company (2018-2023)
8.1.2 China HIV Drugs Revenue by Company (2018-2023)
8.2 China HIV Drugs Market Size by Type
8.2.1 China HIV Drugs Sales Quantity by Type (2018-2034)
8.2.2 China HIV Drugs Revenue by Type (2018-2034)
8.3 China HIV Drugs Market Size by Application
8.3.1 China HIV Drugs Sales Quantity by Application (2018-2034)
8.3.2 China HIV Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC HIV Drugs Sales by Company
9.1.1 APAC HIV Drugs Sales Quantity by Company (2018-2023)
9.1.2 APAC HIV Drugs Revenue by Company (2018-2023)
9.2 APAC HIV Drugs Market Size by Type
9.2.1 APAC HIV Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC HIV Drugs Revenue by Type (2018-2034)
9.3 APAC HIV Drugs Market Size by Application
9.3.1 APAC HIV Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC HIV Drugs Revenue by Application (2018-2034)
9.4 APAC HIV Drugs Market Size by Region
9.4.1 APAC HIV Drugs Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC HIV Drugs Revenue by Region (2018-2034)
9.4.3 APAC HIV Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America HIV Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America HIV Drugs Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America HIV Drugs Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America HIV Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America HIV Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America HIV Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America HIV Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America HIV Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America HIV Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America HIV Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America HIV Drugs Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America HIV Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America HIV Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Information
11.1.2 Bristol-Myers Squibb Overview
11.1.3 Bristol-Myers Squibb HIV Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Bristol-Myers Squibb HIV Drugs Products and Services
11.1.5 Bristol-Myers Squibb HIV Drugs SWOT Analysis
11.1.6 Bristol-Myers Squibb Recent Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Information
11.2.2 Gilead Sciences Overview
11.2.3 Gilead Sciences HIV Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Gilead Sciences HIV Drugs Products and Services
11.2.5 Gilead Sciences HIV Drugs SWOT Analysis
11.2.6 Gilead Sciences Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Information
11.3.2 GlaxoSmithKline Overview
11.3.3 GlaxoSmithKline HIV Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 GlaxoSmithKline HIV Drugs Products and Services
11.3.5 GlaxoSmithKline HIV Drugs SWOT Analysis
11.3.6 GlaxoSmithKline Recent Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Information
11.4.2 Johnson & Johnson Overview
11.4.3 Johnson & Johnson HIV Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Johnson & Johnson HIV Drugs Products and Services
11.4.5 Johnson & Johnson HIV Drugs SWOT Analysis
11.4.6 Johnson & Johnson Recent Developments
11.5 Merck
11.5.1 Merck Company Information
11.5.2 Merck Overview
11.5.3 Merck HIV Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Merck HIV Drugs Products and Services
11.5.5 Merck HIV Drugs SWOT Analysis
11.5.6 Merck Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 HIV Drugs Value Chain Analysis
12.2 HIV Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 HIV Drugs Production Mode & Process
12.4 HIV Drugs Sales and Marketing
12.4.1 HIV Drugs Sales Channels
12.4.2 HIV Drugs Distributors
12.5 HIV Drugs Customers
13 Market Dynamics
13.1 HIV Drugs Industry Trends
13.2 HIV Drugs Market Drivers
13.3 HIV Drugs Market Challenges
13.4 HIV Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global HIV Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Multi-Class Combination Products
Table 3. Major Manufacturers of Nucleoside Reverse Transcriptase Inhibitors
Table 4. Major Manufacturers of Non-Nucleoside Reverse Transcriptase Inhibitors
Table 5. Major Manufacturers of Protease Inhibitors
Table 6. Major Manufacturers of Fusion Inhibitors
Table 7. Major Manufacturers of Entry Inhibitors - CCR5 Co-Receptor Antagonist
Table 8. Major Manufacturers of HIV Integrase Strand Transfer Inhibitors
Table 9. Global HIV Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global HIV Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 11. Global HIV Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 12. Global HIV Drugs Revenue Market Share by Region (2018-2023)
Table 13. Global HIV Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 14. Global HIV Drugs Revenue Market Share by Region (2024-2034)
Table 15. Global HIV Drugs Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 16. Global HIV Drugs Sales by Region (2018-2023) & (K Units)
Table 17. Global HIV Drugs Sales Market Share by Region (2018-2023)
Table 18. Global HIV Drugs Sales by Region (2024-2034) & (K Units)
Table 19. Global HIV Drugs Sales Market Share by Region (2024-2034)
Table 20. Global HIV Drugs Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 21. Global HIV Drugs Sales Quantity Share by Manufacturers (2018-2023)
Table 22. Global HIV Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 23. Global HIV Drugs Revenue Share by Manufacturers (2018-2023)
Table 24. Global HIV Drugs Price by Manufacturers 2018-2023 (USD/Unit)
Table 25. Global Key Players of HIV Drugs, Industry Ranking, 2021 VS 2024
Table 26. Global HIV Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 27. Global HIV Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HIV Drugs as of 2024)
Table 28. Global Key Manufacturers of HIV Drugs, Manufacturing Base Distribution and Headquarters
Table 29. Global Key Manufacturers of HIV Drugs, Product Offered and Application
Table 30. Global Key Manufacturers of HIV Drugs, Date of Enter into This Industry
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global HIV Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 33. Global HIV Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 34. Global HIV Drugs Sales Quantity Share by Type (2018-2023)
Table 35. Global HIV Drugs Sales Quantity Share by Type (2024-2034)
Table 36. Global HIV Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 37. Global HIV Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 38. Global HIV Drugs Revenue Share by Type (2018-2023)
Table 39. Global HIV Drugs Revenue Share by Type (2024-2034)
Table 40. HIV Drugs Price by Type (2018-2023) & (USD/Unit)
Table 41. Global HIV Drugs Price Forecast by Type (2024-2034) & (USD/Unit)
Table 42. Global HIV Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 43. Global HIV Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 44. Global HIV Drugs Sales Quantity Share by Application (2018-2023)
Table 45. Global HIV Drugs Sales Quantity Share by Application (2024-2034)
Table 46. Global HIV Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 47. Global HIV Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 48. Global HIV Drugs Revenue Share by Application (2018-2023)
Table 49. Global HIV Drugs Revenue Share by Application (2024-2034)
Table 50. HIV Drugs Price by Application (2018-2023) & (USD/Unit)
Table 51. Global HIV Drugs Price Forecast by Application (2024-2034) & (USD/Unit)
Table 52. North America HIV Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 53. North America HIV Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 54. North America HIV Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 55. North America HIV Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 56. North America HIV Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 57. North America HIV Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 58. North America HIV Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 59. North America HIV Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 60. North America HIV Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 61. North America HIV Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 62. North America HIV Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 63. North America HIV Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 64. North America HIV Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 65. North America HIV Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 66. North America HIV Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 67. Europe HIV Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 68. Europe HIV Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 69. Europe HIV Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 70. Europe HIV Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 71. Europe HIV Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 72. Europe HIV Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 73. Europe HIV Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 74. Europe HIV Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 75. Europe HIV Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 76. Europe HIV Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 77. Europe HIV Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 78. Europe HIV Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 79. Europe HIV Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 80. Europe HIV Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 81. Europe HIV Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 82. China HIV Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 83. China HIV Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 84. China HIV Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 85. China HIV Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 86. China HIV Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 87. China HIV Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 88. China HIV Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 89. China HIV Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 90. China HIV Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 91. China HIV Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 92. APAC HIV Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 93. APAC HIV Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 94. APAC HIV Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 95. APAC HIV Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 96. APAC HIV Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 97. APAC HIV Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 98. APAC HIV Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 99. APAC HIV Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 100. APAC HIV Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 101. APAC HIV Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 102. APAC HIV Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 103. APAC HIV Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 104. APAC HIV Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 105. APAC HIV Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 106. APAC HIV Drugs Sales Quantity by Region (2024-2034) & (K Units)
Table 107. Middle East, Africa and Latin America HIV Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 108. Middle East, Africa and Latin America HIV Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 109. Middle East, Africa and Latin America HIV Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 110. Middle East, Africa and Latin America HIV Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 111. Middle East, Africa and Latin America HIV Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 112. Middle East, Africa and Latin America HIV Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America HIV Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 114. Middle East, Africa and Latin America HIV Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 115. Middle East, Africa and Latin America HIV Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 116. Middle East, Africa and Latin America HIV Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America HIV Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 118. Middle East, Africa and Latin America HIV Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 119. Middle East, Africa and Latin America HIV Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 120. Middle East, Africa and Latin America HIV Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 121. Middle East, Africa and Latin America HIV Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 122. Bristol-Myers Squibb Company Information
Table 123. Bristol-Myers Squibb Description and Overview
Table 124. Bristol-Myers Squibb HIV Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 125. Bristol-Myers Squibb HIV Drugs Product and Services
Table 126. Bristol-Myers Squibb HIV Drugs SWOT Analysis
Table 127. Bristol-Myers Squibb Recent Developments
Table 128. Gilead Sciences Company Information
Table 129. Gilead Sciences Description and Overview
Table 130. Gilead Sciences HIV Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 131. Gilead Sciences HIV Drugs Product and Services
Table 132. Gilead Sciences HIV Drugs SWOT Analysis
Table 133. Gilead Sciences Recent Developments
Table 134. GlaxoSmithKline Company Information
Table 135. GlaxoSmithKline Description and Overview
Table 136. GlaxoSmithKline HIV Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 137. GlaxoSmithKline HIV Drugs Product and Services
Table 138. GlaxoSmithKline HIV Drugs SWOT Analysis
Table 139. GlaxoSmithKline Recent Developments
Table 140. Johnson & Johnson Company Information
Table 141. Johnson & Johnson Description and Overview
Table 142. Johnson & Johnson HIV Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 143. Johnson & Johnson HIV Drugs Product and Services
Table 144. Johnson & Johnson HIV Drugs SWOT Analysis
Table 145. Johnson & Johnson Recent Developments
Table 146. Merck Company Information
Table 147. Merck Description and Overview
Table 148. Merck HIV Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 149. Merck HIV Drugs Product and Services
Table 150. Merck HIV Drugs SWOT Analysis
Table 151. Merck Recent Developments
Table 152. Key Raw Materials Lists
Table 153. Raw Materials Key Suppliers Lists
Table 154. HIV Drugs Distributors List
Table 155. HIV Drugs Customers List
Table 156. HIV Drugs Market Trends
Table 157. HIV Drugs Market Drivers
Table 158. HIV Drugs Market Challenges
Table 159. HIV Drugs Market Restraints
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
List of Figures
Figure 1. HIV Drugs Product Picture
Figure 2. Global HIV Drugs Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global HIV Drugs Market Share by Type in 2024 & 2034
Figure 4. Multi-Class Combination Products Product Picture
Figure 5. Nucleoside Reverse Transcriptase Inhibitors Product Picture
Figure 6. Non-Nucleoside Reverse Transcriptase Inhibitors Product Picture
Figure 7. Protease Inhibitors Product Picture
Figure 8. Fusion Inhibitors Product Picture
Figure 9. Entry Inhibitors - CCR5 Co-Receptor Antagonist Product Picture
Figure 10. HIV Integrase Strand Transfer Inhibitors Product Picture
Figure 11. Global HIV Drugs Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 12. Global HIV Drugs Market Share by Application in 2024 & 2034
Figure 13. Hospital Pharmacies
Figure 14. Retail Pharmacies
Figure 15. Online Pharmacies
Figure 16. Others
Figure 17. HIV Drugs Report Years Considered
Figure 18. Global HIV Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 19. Global HIV Drugs Revenue 2018-2034 (US$ Million)
Figure 20. Global HIV Drugs Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 21. Global HIV Drugs Sales Quantity 2018-2034 (K Units)
Figure 22. Global HIV Drugs Sales Quantity Market Share by Region (2018-2023)
Figure 23. Global HIV Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 24. North America HIV Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. North America HIV Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Europe HIV Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Europe HIV Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 28. China HIV Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. China HIV Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 30. APAC HIV Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 31. APAC HIV Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 32. Middle East, Africa and Latin America HIV Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 33. Middle East, Africa and Latin America HIV Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 34. The Top 10 and Top 5 Players Market Share by HIV Drugs Sales Quantity in 2024
Figure 35. The Top 10 and Top 5 Players Market Share by HIV Drugs Revenue in 2024
Figure 36. HIV Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 37. Global HIV Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 38. Global HIV Drugs Revenue Market Share by Type (2018-2034)
Figure 39. Global HIV Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 40. Global HIV Drugs Revenue Market Share by Application (2018-2034)
Figure 41. North America HIV Drugs Revenue Market Share by Company in 2024
Figure 42. North America HIV Drugs Sales Quantity Market Share by Company in 2024
Figure 43. North America HIV Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 44. North America HIV Drugs Revenue Market Share by Type (2018-2034)
Figure 45. North America HIV Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 46. North America HIV Drugs Revenue Market Share by Application (2018-2034)
Figure 47. North America HIV Drugs Revenue Share by Country (2018-2034)
Figure 48. North America HIV Drugs Sales Quantity Share by Country (2018-2034)
Figure 49. U.S. HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 50. Canada HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 51. Europe HIV Drugs Sales Quantity Market Share by Company in 2024
Figure 52. Europe HIV Drugs Revenue Market Share by Company in 2024
Figure 53. Europe HIV Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 54. Europe HIV Drugs Revenue Market Share by Type (2018-2034)
Figure 55. Europe HIV Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 56. Europe HIV Drugs Revenue Market Share by Application (2018-2034)
Figure 57. Europe HIV Drugs Revenue Share by Country (2018-2034)
Figure 58. Europe HIV Drugs Sales Quantity Share by Country (2018-2034)
Figure 59. Germany HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 60. France HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 61. U.K. HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 62. Italy HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 63. Russia HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 64. China HIV Drugs Sales Quantity Market Share by Company in 2024
Figure 65. China HIV Drugs Revenue Market Share by Company in 2024
Figure 66. China HIV Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 67. China HIV Drugs Revenue Market Share by Type (2018-2034)
Figure 68. China HIV Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 69. China HIV Drugs Revenue Market Share by Application (2018-2034)
Figure 70. APAC HIV Drugs Sales Quantity Market Share by Company in 2024
Figure 71. APAC HIV Drugs Revenue Market Share by Company in 2024
Figure 72. APAC HIV Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 73. APAC HIV Drugs Revenue Market Share by Type (2018-2034)
Figure 74. APAC HIV Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 75. APAC HIV Drugs Revenue Market Share by Application (2018-2034)
Figure 76. APAC HIV Drugs Revenue Share by Region (2018-2034)
Figure 77. APAC HIV Drugs Sales Quantity Share by Region (2018-2034)
Figure 78. Japan HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 79. South Korea HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 80. China Taiwan HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 81. Southeast Asia HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 82. India HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 83. Middle East, Africa and Latin America HIV Drugs Sales Quantity Market Share by Company in 2024
Figure 84. Middle East, Africa and Latin America HIV Drugs Revenue Market Share by Company in 2024
Figure 85. Middle East, Africa and Latin America HIV Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 86. Middle East, Africa and Latin America HIV Drugs Revenue Market Share by Type (2018-2034)
Figure 87. Middle East, Africa and Latin America HIV Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 88. Middle East, Africa and Latin America HIV Drugs Revenue Market Share by Application (2018-2034)
Figure 89. Middle East, Africa and Latin America HIV Drugs Sales Quantity Share by Country (2018-2034)
Figure 90. Middle East, Africa and Latin America HIV Drugs Revenue Share by Country (2018-2034)
Figure 91. Brazil HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 92. Mexico HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 93. Turkey HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 94. Israel HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 95. GCC Countries HIV Drugs Revenue (2018-2034) & (US$ Million)
Figure 96. HIV Drugs Value Chain
Figure 97. HIV Drugs Production Process
Figure 98. Channels of Distribution (Direct Vs Distribution)
Figure 99. Distributors Profiles
Figure 100. Bottom-up and Top-down Approaches for This Report
Figure 101. Data Triangulation
Figure 102. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries